Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

29.09 -0.27 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 725,222
Open 29.50
Bid (Size) 27.85 (1)
Ask (Size) 30.30 (1)
Prev. Close 29.36
Today's Range 28.72 - 29.56
52wk Range 6.910 - 29.56
Shares Outstanding 57,251,254
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
Via Talk Markets
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
Via ACCESSWIRE

Performance

YTD
+169.85%
+169.85%
1 Month
+16.27%
+16.27%
3 Month
+16.36%
+16.36%
6 Month
+284.28%
+284.28%
1 Year
+268.69%
+268.69%

More News

Read More
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Via ACCESSWIRE
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
Via Investor Brand Network
Protagonist Therapeutics: Q1 Earnings Insights
Via Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
Via Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Via Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
Via Benzinga
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
Via Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
Via Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
Via The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Via ACCESSWIRE
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Top 5 Health Care Stocks That May Collapse In February
Via Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.